Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer

Listen to Nilofer S. Azad, MD, and Kanwal Raghav, MD, as they discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC.
Nilofer S. Azad, MD
Kanwal Raghav, MD
Released: April 6, 2022

In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:

  • Current use of regorafenib and TAS-102 monotherapy
  • Combination therapy with regorafenib and PD-1 inhibitors
  • Adding bevacizumab to TAS-102

Acknowledgements

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Information on this Educational Activity

Faculty

Nilofer S. Azad, MD

Associate Professor, Oncology
Johns Hopkins
Baltimore, Maryland

Nilofer S. Azad, MD, has disclosed that she has received funds for research support from Astex, Agios, Bayer, Bristol-Myers Squibb, Daiichi, Debio, Incyte, Intensity, Lilly, Merck/EMD Serono, Syndax, and Taiho and consulting fees from Merck/EMD Serono and QED.
Kanwal Raghav, MD

Associate Professor
GI Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas

Kanwal Raghav, MD, has disclosed that he has received funds for research support from Bayer, Daiichi, Medimmune, Merck, and Roche; consulting fess from Bayer and Daiichi; and fees for non-CME/CE services from Daiichi.

Program Medium

This program has been made available online.

Related Content

Data on dostarlimab for locally advanced, mismatch repair-deficient rectal cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Expanded results from CheckMate 648 of first-line nivolumab + chemotherapy or ipilimumab vs chemotherapy alone in advanced esophageal squamous cell cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 13, 2022

CAIRO5: FOLFOXIRI + bevacizumab vs FOLFOX/FOLFIRI + bevacizumab in initially unresectable colorectal liver metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Data from the CONKO-007 trial of chemoradiotherapy vs chemotherapy for locally advanced pancreatic cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings